Role of 18 FDG PET/CT in Detecting Primary Tumors in Patients with Carcinoma of Unknown Primary: Single-Center Cross-Sectional Study from 2017 to 2023 (Extension Study).

IF 0.9 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING World Journal of Nuclear Medicine Pub Date : 2024-11-19 eCollection Date: 2025-03-01 DOI:10.1055/s-0044-1795101
Nosheen Fatima, Mina Laiq, Muhammad Rafay, Sara Muhammad Azam, Maseeh Uz Zaman
{"title":"Role of <sup>18</sup> FDG PET/CT in Detecting Primary Tumors in Patients with Carcinoma of Unknown Primary: Single-Center Cross-Sectional Study from 2017 to 2023 (Extension Study).","authors":"Nosheen Fatima, Mina Laiq, Muhammad Rafay, Sara Muhammad Azam, Maseeh Uz Zaman","doi":"10.1055/s-0044-1795101","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background</b>  Carcinoma of unknown primary (CUP) is a diverse group of cancers in which the primary tumor site remains occult despite detailed investigations. This is an extension of a published parent study with a smaller cohort, to further validate the published facts of detection efficiency of 18F-fluorodeoxyglucose positron emission tomography/computed tomography ( <sup>18</sup> FDG PET/CT) in patients with CUP over a larger sample from 2017 to 2023. <b>Methods</b>  Patients with CUP referred for <sup>18</sup> FDG PET/CT scan for detection of primary sites during the study period were recruited. <sup>18</sup> FDG PET/CT scan was acquired using a standardized protocol, and patients with suspected primary sites underwent biopsies. Scan findings and biopsy results were analyzed to find the detection rate, sensitivity, area under the curve (AUC), and positive predictive value (PPV). As no biopsy was performed in cases with negative scan, these cases were considered false negatives (FNs). <b>Results</b>  Total 230 patients with CUP were included with similar demographic trend (mean age: 58 ± 14 years; 63% male and 37% female; mean body mass index: 26.82 ± 5.4 kg/m <sup>2</sup> ); 138/230 (60 vs. 74% in parent study) patients were found to have a hypermetabolic focus suggestive of primary tumor sites and subjected to biopsy which turned out positive in 127/138 (true positive [TP]: 92 vs. 76% in parent study) and negative in 11/138 (true negative [TN]: 8 vs. 24% in parent study). Sensitivity and PPV of <sup>18</sup> FDG PET/CT were 58 and 92%, respectively (68 and 76%, respectively, in parent study). The remaining 92/230 (40%) patients with negative <sup>18</sup> FDG PET/CT for primary focus did not have biopsy. No significant demographic difference was seen in patients with TP and FN studies ( <i>p</i>  > 0.05). Receiver operating characteristics (ROC) curve revealed fair diagnostic strength of <sup>18</sup> FDG PET/CT for detecting unknown primary (AUC 0.710; <i>p</i> ≤ 0.05; standard error = 0.0167; confidence interval: 0.647-0.768; vs. nonsignificant in parent study). <b>Conclusion</b>  We conclude that this extension study with a larger cohort compared with the parent study has found a similar detection efficiency of <sup>18</sup> FDG PET/CT for identifying primary tumor in patients with CUP (58 vs. 57%) but with better PPV and sensitivity. Upfront use of <sup>18</sup> FDG PET/CT in CUP could preclude the use of many futile diagnostic procedures. Furthermore, the use of tumor-specific PET tracers, higher resolution scanners, and acquiring delayed images in patients with negative <sup>18</sup> FDG study could reduce FN results in patients with CUP.</p>","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":"24 1","pages":"57-63"},"PeriodicalIF":0.9000,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11828639/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Nuclear Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/s-0044-1795101","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

Abstract

Background  Carcinoma of unknown primary (CUP) is a diverse group of cancers in which the primary tumor site remains occult despite detailed investigations. This is an extension of a published parent study with a smaller cohort, to further validate the published facts of detection efficiency of 18F-fluorodeoxyglucose positron emission tomography/computed tomography ( 18 FDG PET/CT) in patients with CUP over a larger sample from 2017 to 2023. Methods  Patients with CUP referred for 18 FDG PET/CT scan for detection of primary sites during the study period were recruited. 18 FDG PET/CT scan was acquired using a standardized protocol, and patients with suspected primary sites underwent biopsies. Scan findings and biopsy results were analyzed to find the detection rate, sensitivity, area under the curve (AUC), and positive predictive value (PPV). As no biopsy was performed in cases with negative scan, these cases were considered false negatives (FNs). Results  Total 230 patients with CUP were included with similar demographic trend (mean age: 58 ± 14 years; 63% male and 37% female; mean body mass index: 26.82 ± 5.4 kg/m 2 ); 138/230 (60 vs. 74% in parent study) patients were found to have a hypermetabolic focus suggestive of primary tumor sites and subjected to biopsy which turned out positive in 127/138 (true positive [TP]: 92 vs. 76% in parent study) and negative in 11/138 (true negative [TN]: 8 vs. 24% in parent study). Sensitivity and PPV of 18 FDG PET/CT were 58 and 92%, respectively (68 and 76%, respectively, in parent study). The remaining 92/230 (40%) patients with negative 18 FDG PET/CT for primary focus did not have biopsy. No significant demographic difference was seen in patients with TP and FN studies ( p  > 0.05). Receiver operating characteristics (ROC) curve revealed fair diagnostic strength of 18 FDG PET/CT for detecting unknown primary (AUC 0.710; p ≤ 0.05; standard error = 0.0167; confidence interval: 0.647-0.768; vs. nonsignificant in parent study). Conclusion  We conclude that this extension study with a larger cohort compared with the parent study has found a similar detection efficiency of 18 FDG PET/CT for identifying primary tumor in patients with CUP (58 vs. 57%) but with better PPV and sensitivity. Upfront use of 18 FDG PET/CT in CUP could preclude the use of many futile diagnostic procedures. Furthermore, the use of tumor-specific PET tracers, higher resolution scanners, and acquiring delayed images in patients with negative 18 FDG study could reduce FN results in patients with CUP.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
18 FDG PET/CT在未知原发癌患者原发肿瘤检测中的作用:2017 - 2023年单中心横断面研究(扩展研究)
背景:未知原发癌(CUP)是一种多种类型的癌症,尽管进行了详细的调查,但原发肿瘤部位仍不清楚。本研究是一项已发表的母研究的延伸,研究对象较小,旨在进一步验证已发表的18f -氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描(18fdg PET/CT)在2017年至2023年期间对CUP患者检测效率的事实。方法选取在研究期间行18次FDG PET/CT扫描检测原发部位的CUP患者。采用标准化方案进行FDG PET/CT扫描,疑似原发灶的患者接受活检。分析扫描结果和活检结果的检出率、敏感性、曲线下面积(AUC)和阳性预测值(PPV)。由于扫描阴性的病例未进行活检,这些病例被认为是假阴性(FNs)。结果共纳入230例CUP患者,人口统计学趋势相似(平均年龄:58±14岁;男性占63%,女性占37%;平均体重指数:26.82±5.4 kg/ m2);138/230例(60例,本研究为74%)患者发现高代谢灶提示原发肿瘤部位,并进行活检,127/138例为阳性(真阳性[TP]: 92例,本研究为76%),11/138例为阴性(真阴性[TN]: 8例,本研究为24%)。18个FDG PET/CT的灵敏度和PPV分别为58%和92%(亲本研究分别为68%和76%)。其余92/230例(40%)FDG PET/CT原发病灶阴性的患者未行活检。TP组和FN组患者的人口统计学差异无统计学意义(p < 0.05)。受试者工作特征(ROC)曲线显示18 FDG PET/CT对未知原发病灶的诊断强度较好(AUC 0.710;P≤0.05;标准误差= 0.0167;置信区间:0.647-0.768;在父母研究中不显著)。我们得出结论,与母体研究相比,该扩展研究的队列更大,发现18 FDG PET/CT在识别CUP患者原发肿瘤方面的检测效率相似(58%对57%),但PPV和灵敏度更高。在CUP中预先使用18fdg PET/CT可以避免使用许多无用的诊断程序。此外,在FDG阴性的患者中使用肿瘤特异性PET示踪剂、高分辨率扫描仪和获取延迟图像可以降低CUP患者的FN结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
World Journal of Nuclear Medicine
World Journal of Nuclear Medicine RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING-
自引率
16.70%
发文量
118
审稿时长
48 weeks
期刊最新文献
ARTnet Perspectives and Contributions to Theranostics. Radiotheranostics in Low- and Middle-Income Countries: Challenges, Practice, and Prospects. Individualized Dosimetry to Guide LuTATE Therapy in Pediatric Neuroblastoma. Theranostics Implementation: Opportunities and Challenges. Multidisciplinary Perspectives of Clinical Trials in Theranostics.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1